These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20124232)

  • 1. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies.
    Rosenbloom J; Castro SV; Jimenez SA
    Ann Intern Med; 2010 Feb; 152(3):159-66. PubMed ID: 20124232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
    Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
    Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-beta signaling in vascular fibrosis.
    Ruiz-Ortega M; Rodríguez-Vita J; Sanchez-Lopez E; Carvajal G; Egido J
    Cardiovasc Res; 2007 May; 74(2):196-206. PubMed ID: 17376414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibitory effect of ginsan on TGF-β mediated fibrotic process.
    Ahn JY; Kim MH; Lim MJ; Park S; Lee SL; Yun YS; Song JY
    J Cell Physiol; 2011 May; 226(5):1241-7. PubMed ID: 20945375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad3 as a mediator of the fibrotic response.
    Flanders KC
    Int J Exp Pathol; 2004 Apr; 85(2):47-64. PubMed ID: 15154911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.
    Chaudhary NI; Roth GJ; Hilberg F; Müller-Quernheim J; Prasse A; Zissel G; Schnapp A; Park JE
    Eur Respir J; 2007 May; 29(5):976-85. PubMed ID: 17301095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Transforming growth factor-beta and its receptors in scleroderma].
    QIAN H; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):415-21. PubMed ID: 19693982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis.
    Verrecchia F; Mauviel A; Farge D
    Autoimmun Rev; 2006 Oct; 5(8):563-9. PubMed ID: 17027893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
    Negri AL
    J Nephrol; 2004; 17(4):496-503. PubMed ID: 15372410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic fibrogenesis: the puzzle of interacting cells, fibrogenic cytokines, regulatory loops, and extracellular matrix molecules.
    Gressner AM
    Z Gastroenterol; 1992 Mar; 30 Suppl 1():5-16. PubMed ID: 1449018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease.
    Beyer C; Distler JH
    Biochim Biophys Acta; 2013 Jul; 1832(7):897-904. PubMed ID: 22728287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring anti-TGF-β therapies in cancer and fibrosis.
    Hawinkels LJ; Ten Dijke P
    Growth Factors; 2011 Aug; 29(4):140-52. PubMed ID: 21718111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
    Chujo S; Shirasaki F; Kawara S; Inagaki Y; Kinbara T; Inaoki M; Takigawa M; Takehara K
    J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role for transforming growth factor-beta (TGF-beta) in human cancer.
    Gold LI
    Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
    Ghosh AK; Bhattacharyya S; Lakos G; Chen SJ; Mori Y; Varga J
    Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors.
    Shi-Wen X; Rodríguez-Pascual F; Lamas S; Holmes A; Howat S; Pearson JD; Dashwood MR; du Bois RM; Denton CP; Black CM; Abraham DJ; Leask A
    Mol Cell Biol; 2006 Jul; 26(14):5518-27. PubMed ID: 16809784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.